Poland’s Health Ministry is simplifying regulations for pharmaceutical advertising aimed at professionals, prioritizing digitization over paper brochures starting April 15th.
Key Information and Supplementary Data
The new regulations introduce a distinction between “key” and “supplementary” data in pharmaceutical advertising. Essential information will continue to be delivered in traditional paper format.
Key data includes the product name, qualitative and quantitative composition of active and excipient substances, pharmaceutical form, details of the responsible party, and availability category.
Digital Access for Detailed Information
Advertisers will now be able to provide supplementary data – such as therapeutic indications, detailed dosage, contraindications, special warnings, and adverse reactions – electronically, via digital platforms or websites.
The availability category remains an exception and must still be provided in traditional paper form, despite being covered by Article 54 of the Pharmaceutical Law.
Impact on Market Participants
The changes will affect approximately 350 pharmaceutical companies, 600,000 healthcare professionals, and the Chief Pharmaceutical Inspectorate (GIF).
Manufacturers and distributors will see cost optimization, while doctors and pharmacists will gain easier digital access to detailed drug information. The GIF will need to adapt its control mechanisms to the new model.
Economic Justification for the Change
The shift to digitization is driven by economic considerations, aiming to minimize the costs associated with physically reproducing and distributing extensive product characteristics to a large number of recipients.
The new regulations promote a more ecological and modern approach to pharmaceutical marketing.